Tissue‐derived extracellular vesicles in cancers and non‐cancer diseases: Present and future

Li, Su-Ran; Man, Qi‐Wen; Gao, Xin; Lin, Hao; Wang, Jing; Su, Fu‐Chuan; Wang, Hanqi; Bu, Lin‐Lin; Liu, Bing; Chen, Gang

doi:10.1002/jev2.12175

Cited by 114 publications

(102 citation statements)

References 201 publications

(258 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified different characteristics between human and mice samples and speculated that it might be caused by the following reasons: (1) We removed blood to eliminate the plasma EVs in all experimental animals but not during treatment of human samples considering of the feasibility. Contamination of blood in tissues has impact on cell viability, EV recovery, and EV proteomic data (Li et al, 2021). ( 2) Deposits in human lung tissues, including air pollutants and particles, may cause differences in EV proteomic data comparing with murine lung EVs.…”

Section:  Discussionmentioning

confidence: 99%

Extracellular vesicles from lung tissue drive bone marrow neutrophil recruitment in inflammation

Liu

Jin

Yang

et al. 2022

J of Extracellular Vesicle

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are single-membrane vesicles that play an essential role in long-range intercellular communications. EV investigation has been explored largely through cell-culture systems, but it remains unclear how physiological EVs exert homeostatic or pathological functions in vivo. Here, we report that lung EVs promote chemotaxis of neutrophils in bone marrow through delivery of double stranded DNA (dsDNA). We have identified and characterized EVs containing dsDNA collected from both human and murine lung tissues using newly developed approaches. Our analysis of EV proteomics together with single-cell RNA sequencing data reveals that type II alveolar epithelial cells are the main source of the lung EVs. Furthermore, we demonstrate that the lung EVs accumulate in bone marrow and enhance neutrophil recruitment under inflammation conditions. Moreover, lung EV-DNA stimulates neutrophils to release the chemokines CXCL1 and CXCL2 via DNA-TLR9 signalling. Our findings establish a molecular basis of lung EVs in enhancement of host immune response to bacterial infection and provide new insights into understanding of vesicle-mediated systematic communications.

show abstract

Section:  Discussionmentioning

confidence: 99%

Extracellular vesicles from lung tissue drive bone marrow neutrophil recruitment in inflammation

Liu

Jin

Yang

et al. 2022

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

“… 15 Tumor-derived EVs can produce cancerous characteristics by transporting cancer-promoting molecules to recipient cells. 35 Given the critical roles of EVs in regulating nontumor cells in the TME, we explored the roles of OSCC-derived sEVs on surrounding normal epithelial cells. We found OSCC-derived sEVs enhance the migration, invasion, proliferation, and EMT of normal epithelial cells but diminish their apoptosis rate.…”

Section: Discussionmentioning

confidence: 99%

Cancer cells corrupt normal epithelial cells through miR-let-7c-rich small extracellular vesicle-mediated downregulation of p53/PTEN

et al. 2022

View full text Add to dashboard Cite

Tumor volume increases continuously in the advanced stage, and aside from the self-renewal of tumor cells, whether the oncogenic transformation of surrounding normal cells is involved in this process is currently unclear. Here, we show that oral squamous cell carcinoma (OSCC)-derived small extracellular vesicles (sEVs) promote the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of normal epithelial cells but delay their apoptosis. In addition, nuclear-cytoplasmic invaginations and multiple nucleoli are observed in sEV-treated normal cells, both of which are typical characteristics of premalignant lesions of OSCC. Mechanistically, miR-let-7c in OSCC-derived sEVs is transferred to normal epithelial cells, leading to the transcriptional inhibition of p53 and inactivation of the p53/PTEN pathway. In summary, we demonstrate that OSCC-derived sEVs promote the precancerous transformation of normal epithelial cells, in which the miR-let-7c/p53/PTEN pathway plays an important role. Our findings reveal that cancer cells can corrupt normal epithelial cells through sEVs, which provides new insight into the progression of OSCC.

show abstract

“…EVs can be broadly classified into three subtypes based on their origins: cell culture-derived EVs, bodily fluid-derived EVs, and tissue-derived EVs [ 20 ]. Nevertheless, because EVs are secreted by cells into body fluids and tissues, cellular secretion represents the primary source of these vesicles.…”

Section: Evs Acquisitionmentioning

confidence: 99%

“…However, other challenges, such as obtaining a therapeutic-scale yield, currently limit the use of Ti-EVs. Feasible solutions for this limitation include the reconstitution of 3D tissue-like structures (organoids), bioreactor-based culture methods, and treatment efficiency enhancement [ 20 ]. However, these technologies are still in their infancy, and require substantial research attention.…”

Section: Evs Acquisitionmentioning

confidence: 99%

Application of engineered extracellular vesicles for targeted tumor therapy

et al. 2022

View full text Add to dashboard Cite

All cells, including prokaryotes and eukaryotes, could release extracellular vesicles (EVs). EVs contain many cellular components, including RNA, and surface proteins, and are essential for maintaining normal intercellular communication and homeostasis of the internal environment. EVs released from different tissues and cells exhibit excellent properties and functions (e.g., targeting specificity, regulatory ability, physical durability, and immunogenicity), rendering them a potential new option for drug delivery and precision therapy. EVs have been demonstrated to transport antitumor drugs for tumor therapy; additionally, EVs' contents and surface substance can be altered to improve their therapeutic efficacy in the clinic by boosting targeting potential and drug delivery effectiveness. EVs can regulate immune system function by affecting the tumor microenvironment, thereby inhibiting tumor progression. Co-delivery systems for EVs can be utilized to further improve the drug delivery efficiency of EVs, including hydrogels and liposomes. In this review, we discuss the isolation technologies of EVs, as well as engineering approaches to their modification. Moreover, we evaluate the therapeutic potential of EVs in tumors, including engineered extracellular vesicles and EVs' co-delivery systems.

show abstract

Tissue‐derived extracellular vesicles in cancers and non‐cancer diseases: Present and future

Cited by 114 publications

References 201 publications

Extracellular vesicles from lung tissue drive bone marrow neutrophil recruitment in inflammation

Extracellular vesicles from lung tissue drive bone marrow neutrophil recruitment in inflammation

Cancer cells corrupt normal epithelial cells through miR-let-7c-rich small extracellular vesicle-mediated downregulation of p53/PTEN

Application of engineered extracellular vesicles for targeted tumor therapy

Contact Info

Product

Resources

About